Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 7 |
| 1.1 List of Tables | 5 | 2 |
| 1.2 List of Figures | 7 | 3 |
| 2 Global Hospital Acquired Bacterial Infections Market: Introduction | 10 | 1 |
| 2.1 GBI Research Report Guidance | 10 | 1 |
| 3 Global Hospital Acquired Bacterial Infections Market: Market Overview | 11 | 8 |
| Introduction | 11 | 1 |
| 3.2 Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market | 12 | 1 |
| 3.2.1 Sales Value | 12 | 1 |
| 3.2.2 Annual Cost of Therapy | 13 | 1 |
| 3.2.3 Treatment Usage Patterns | 14 | 1 |
| 3.2.3.1 Diseased Population | 15 | 1 |
| 3.2.3.2 Diagnosed Population | 16 | 1 |
| 3.2.3.3 Prescription Population | 17 | 1 |
| 3.3 Hospital Acquired Bacterial Infections Market Drivers | 18 | 1 |
| Steady Increase in Elderly and Immuno-Suppressed Population | 18 | 1 |
| 3.3.2 Increase in Average Number of Days Spent In Hospitals | 18 | 1 |
| 3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable | 18 | 1 |
| 3.4 Hospital Acquired Bacterial Infections Market Restraints | 18 | 1 |
| 3.4.1 Increased Penetration of Generics Pose a Serious Threat for Primary Manufacturers | 18 | 1 |
| 3.4.2 Increased Anti-bacterial Surveillance in Hospitals | 18 | 1 |
| 4 Global Hospital Acquired Bacterial Infections Market: Therapeutic Landscape | 19 | 35 |
| 4.1 Hospital Acquired Urinary Tract Infections (UTI) Market | 19 | 1 |
| 4.1.1 Introduction | 19 | 1 |
| Sales Value | 19 | 2 |
| 4.1.3 Annual Cost of Therapy | 21 | 1 |
| 4.1.4 Treatment Usage Patterns | 22 | 1 |
| 4.1.4.1 Diseased Population | 23 | 1 |
| 4.1.4.2 Diagnosed Population | 24 | 1 |
| 4.1.4.3 Prescription Population | 25 | 1 |
| Market Share by Geography | 26 | 2 |
| 4.2 Hospital Acquired Bacterial Pneumonia Market | 28 | 1 |
| Introduction | 28 | 1 |
| 4.2.2 Sales Value | 28 | 2 |
| 4.2.3 Annual Cost of Therapy | 30 | 1 |
| 4.2.4 Treatment Usage Patterns | 31 | 1 |
| Diseased Population | 32 | 1 |
| 4.2.4.2 Diagnosed Population | 33 | 1 |
| 4.2.4.3 Prescription Population | 34 | 1 |
| 4.2.5 Market Share by Geography | 35 | 2 |
| 4.3 Hospital Acquired Bacterial Surgical Site Infections Market | 37 | 1 |
| 4.3.1 Introduction | 37 | 1 |
| 4.3.2 Sales Value | 37 | 1 |
| 4.3.3 Annual Cost of Therapy | 38 | 1 |
| 4.3.4 Treatment Usage Patterns | 39 | 1 |
| 4.3.4.1 Diseased Population | 40 | 1 |
| 4.3.4.2 Diagnosed Population | 41 | 1 |
| 4.3.4.3 Prescription Population | 42 | 1 |
| 4.3.5 Market Share by Geography | 43 | 2 |
| 4.4 Hospital Acquired Bacterial Blood Stream Infections (BSI) Market | 45 | 1 |
| 4.4.1 Introduction | 45 | 1 |
| Sales Value | 45 | 1 |
| 4.4.3 Annual Cost of Therapy | 46 | 1 |
| 4.4.4 Treatment Usage Patterns | 47 | 1 |
| 4.4.4.1 Diseased Population | 48 | 1 |
| 4.4.4.2 Diagnosed Population | 49 | 1 |
| 4.4.4.3 Prescription Population | 50 | 1 |
| 4.4.5 Market Share by Geography | 51 | 3 |
| 5 Global Hospital Acquired Bacterial Infections Market: Geographical Landscape | 54 | 20 |
| 5.1 Geographical Break-up | 54 | 2 |
| 5.2 The US | 56 | 1 |
| 5.2.1 Sales Value | 56 | 1 |
| 5.2.2 Annual Cost of Therapy | 57 | 1 |
| 5.2.3 Treatment Usage Patterns | 58 | 1 |
| 5.2.3.1 Diseased Population | 59 | 1 |
| 5.2.3.2 Diagnosed Population | 60 | 1 |
| 5.2.3.3 Prescription Population | 61 | 1 |
| 5.3 Top Five Countries in Europe | 62 | 1 |
| 5.3.1 Sales Value | 62 | 1 |
| 5.3.2 Annual Cost of Therapy | 63 | 1 |
| 5.3.3 Treatment Usage Patterns | 64 | 1 |
| 5.3.3.1 Diseased Population | 65 | 1 |
| 5.3.3.2 Diagnosed Population | 66 | 1 |
| 5.3.3.3 Prescription Population | 67 | 1 |
| 5.4 Japan | 68 | 1 |
| 5.4.1 Sales Value | 68 | 1 |
| 5.4.2 Annual Cost of Therapy | 69 | 1 |
| 5.4.3 Treatment Usage Patterns | 70 | 1 |
| 5.4.3.1 Diseased Population | 71 | 1 |
| 5.4.3.2 Diagnosed Population | 72 | 1 |
| 5.4.3.3 Prescription Population | 73 | 1 |
| 6 Global Hospital Acquired Bacterial Infections: Pipeline Analysis | 74 | 6 |
| 6.1 Profiles of Key Late Stage Drugs | 74 | 1 |
| 6.1.1 NVC-422 | 74 | 1 |
| 6.1.1.1 Overview | 74 | 1 |
| 6.1.1.2 Mechanism of Action | 74 | 1 |
| 6.1.1.3 Clinical Study Details | 74 | 1 |
| 6.1.2 IC-43 | 75 | 1 |
| 6.1.2.1 Overview | 75 | 1 |
| 6.1.2.2 Mechanism of Action | 75 | 1 |
| 6.1.2.3 Clinical Study Details | 75 | 1 |
| 6.1.3 Torizolid | 76 | 1 |
| 6.1.3.1 Overview | 76 | 1 |
| 6.1.3.2 Mechanism of Action | 76 | 1 |
| 6.1.3.3 Clinical Study Details | 76 | 1 |
| 6.1.4 KBPA-101 | 77 | 1 |
| 6.1.4.1 Overview | 77 | 1 |
| 6.1.4.2 Mechanism of Action | 77 | 1 |
| 6.1.4.3 Clinical Study Details | 78 | 1 |
| 6.1.5 hLF1-11 | 78 | 1 |
| 6.1.5.1 Overview | 78 | 1 |
| 6.1.5.2 Mechanism of Action | 78 | 1 |
| 6.1.5.3 Clinical Study Details | 79 | 1 |
| 6.2 Pipeline Drugs by Phase of Development | 79 | 1 |
| 7 Global Hospital Acquired Bacterial Infections Market: Competitive Landscape | 80 | 5 |
| 7.1 Competitive Profiling | 80 | 1 |
| 7.1.1 Johnson &Johnson (J&J) | 80 | 1 |
| 7.1.1.1 Overview | 80 | 1 |
| 7.1.1.2 Product Portfolio | 80 | 1 |
| 7.1.2 Pfizer | 81 | 1 |
| 7.1.2.1 Overview | 81 | 1 |
| 7.1.2.2 Product Portfolio | 82 | 1 |
| 7.1.3 Cubist Pharmaceuticals | 83 | 1 |
| 7.1.3.1 Overview | 83 | 1 |
| 7.1.3.2 Product Portfolio | 83 | 1 |
| 7.1.4 Bayer | 83 | 1 |
| 7.1.4.1 Overview | 83 | 1 |
| 7.1.4.2 Product Portfolio | 84 | 1 |
| 8 Global Hospital Acquired Bacterial Infections Market: Strategic Consolidations | 85 | 7 |
| 8.1 Overview | 85 | 1 |
| M&A Deals by Geography | 85 | 1 |
| 8.3 M&A Deals by Value | 85 | 1 |
| 8.4 M&A Deals by Deal Type | 86 | 1 |
| 8.4.1 AstraZeneca Completed the Acquisition of Novexel SA in March 2010 | 87 | 1 |
| 8.4.2 Pharma Omnium International Acquired Mutabilis in July 2009 | 87 | 1 |
| 8.4.3 Hilton Pharma Merges with Sami Pharmaceuticals in November 2008 | 87 | 1 |
| 8.4.4 Phylogica Acquired Additional 63% Stake in Dynamic Microbials in November 2008 | 87 | 1 |
| 8.4.5 Sanofi Pasteur Acquired Acambis in September 2008 | 87 | 1 |
| 8.5 R&D Licensing Agreements | 88 | 1 |
| 8.5.1 Major Licensing Agreements | 89 | 1 |
| 8.5.1.1 Anacor Pharmaceuticals Enters Into Licensing Agreement with GlaxoSmithKline in July 2010 | 89 | 1 |
| 8.5.1.2 e-Therapeutics Enters Into Licensing Agreement with Khandelwal Laboratories in February 2009 | 90 | 1 |
| 8.5.1.3 Basilea Pharmaceutica Enters Into Licensing and Development Agreement with Cilag AG International in February 2005 | 90 | 1 |
| 8.5.1.4 Astellas Pharma Enters Into Licensing Agreement with Theravance in November 2005 | 90 | 1 |
| 8.5.1.5 MedImmune Enters Into License Agreement with GlaxoSmithKline in August 2005 | 91 | 1 |
| 9 Global Hospital Acquired Bacterial Infections Market: Appendix | 92 | 6 |
| 9.1 Market Definitions | 92 | 1 |
| 9.2 Abbreviations | 92 | 1 |
| 9.3 Research Methodology | 93 | 4 |
| 9.3.1 Coverage | 93 | 1 |
| 9.3.2 Secondary Research | 93 | 1 |
| 9.3.3 Primary Research | 93 | 1 |
| 9.3.4 Forecasts | 94 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 94 | 2 |
| 9.3.5 Expert Panel Validation | 96 | 1 |
| 9.4 Contact Us | 97 | 1 |
| 9.5 Disclaimer | 97 | 1 |
| 9.6 Sources | 97 | 1 |